8-K: Lexeo Therapeutics Announces Positive Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy, Plans Registrational Study

Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2006 in Friedreich Ataxia cardiomyopathy, showing significant improvements in cardiac biomarkers and frataxin expression, paving the way for a registrational study.

Summary

• Lexeo Therapeutics announced positive interim Phase 1/2 clinical data for LX2006 in treating Friedreich Ataxia (FA) cardiomyopathy.
• The data comes from both the Lexeo-sponsored SUNRISE-FA trial and the Weill Cornell Medicine investigator-initiated trial.
• LX2006 treatment showed clinically significant improvements in cardiac biomarkers and functional measures.
• All participants with cardiac biopsies showed increased frataxin protein expression.
• Participants with abnormal left ventricular mass index (LVMI) at baseline achieved a 25% mean reduction in LVMI by 12 months or sooner.
• The company plans to initiate a registrational study by early 2026.
• Lexeo has obtained FDA alignment on key parameters for the registrational study, including co-primary endpoints of LVMI improvement (>10% at 12 months) and frataxin expression increase (any increase from baseline at three months).

Sentiment

Score: 9

Explanation: The document presents highly positive clinical data, FDA alignment, and a clear path forward, suggesting a strong likelihood of success for LX2006. The sentiment is very optimistic.

Positives

• LX2006 shows promise as a potential first-in-class treatment for FA cardiomyopathy.
• The treatment was associated with clinically significant improvements in cardiac biomarkers and functional measures.
• All participants with cardiac biopsies showed increased frataxin protein expression, indicating the drug is working as intended.
• The high-dose cohort achieved a 115% average increase in cardiac frataxin expression.
• LX2006 has been generally well-tolerated in clinical trials.
• The FDA has provided alignment on key parameters for the registrational study, including co-primary endpoints.

Negatives

• One participant experienced a possibly treatment-related Grade 2 event of asymptomatic myocarditis one year after dosing.
• The registrational study is not expected to begin until early 2026, with a potential efficacy readout in 2027, meaning patients will have to wait for a potential treatment.

Risks

• The forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial results, regulatory approvals, and liquidity.
• The relationship between preclinical study results and clinical study results is unpredictable.
• Delays in regulatory filings or failure to receive regulatory approval could impact the timeline for LX2006's development.
• The company's liquidity and capital resources could affect its ability to advance the program.

Future Outlook

Lexeo expects to begin enrollment in a prospective natural history study in Q2 2025 and initiate a registrational study by early 2026, with a potential efficacy readout in 2027.

Management Comments

• Dr. Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics, stated that the data provides strong evidence that LX2006 is acting as a beneficial disease-modifying treatment candidate.
• Dr. Sandi See Tai, Chief Development Officer at Lexeo, believes the data shows LX2006 exceeding the thresholds aligned with the FDA to support accelerated approval in the planned registrational study.

Industry Context

This announcement is significant because Friedreich Ataxia cardiomyopathy has limited treatment options, and cardiac dysfunction is the leading cause of death for these patients. LX2006 represents a potential first-in-class gene therapy addressing the underlying genetic cause of the disease.

Comparison to Industry Standards

• The only approved disease-specific treatment for FA demonstrated efficacy on neurological measures but was not evaluated for the treatment of cardiac dysfunction, highlighting the unmet need that LX2006 aims to address.
• Omaveloxolone is the current standard of care for neurologic symptoms in adults with FA, and LX2006 is expected to be studied alongside it, potentially offering a complementary treatment approach.
• The co-primary endpoints of LVMI reduction and frataxin expression increase align with FDA's requirements for accelerated approval, suggesting a well-defined regulatory pathway for LX2006.

Stakeholder Impact

• The positive results and potential approval of LX2006 could significantly improve the quality of life and life expectancy for individuals with Friedreich Ataxia cardiomyopathy.
• The company's progress benefits shareholders through increased value and potential revenue from a successful product.
• The development of LX2006 could establish Lexeo Therapeutics as a leader in genetic medicine for cardiovascular diseases.

Next Steps

• Begin enrollment for a prospective natural history study in Q2 2025.
• Finalize the registrational trial protocol through ongoing dialogue with regulators.
• Initiate the registrational study by early 2026.
• Assess co-primary endpoints of LVMI reduction and frataxin expression in the registrational study.

Key Dates

Keywords

LX2006, Friedreich Ataxia, Cardiomyopathy, Gene Therapy, Clinical Trial, Frataxin, LVMI, Lexeo Therapeutics, FDA, Accelerated Approval